Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2326-2334

  Raffoux, Emmanuel ^a   Rousselot, Philippe ^a   Poupon, Joël ^a   Daniel, Marie Thérèse ^a   Cassinat, Bruno ^a   Delarue, Richard ^a   Taksin, Anne Laure ^a   Réa, Delphine ^a   Buzyn, Agnès ^a   Tibi, Annick ^a   Lebbé, Geneviève ^a   Cimerman, Patricia ^a   Chomienne, Christine ^a   Fermand, Jean Paul ^a   De Thé, Hugues ^a   Degos, Laurent ^a   Hermine, Olivier ^a   Dombret, Hervé ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKOCYTOSIS; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; NONPARAMETRIC TEST; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; RECURRENCE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN;

EID: 0037811741     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.149     Document Type: Article

References (49)

1. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215, 1999
2. Fenaux P, Chomienne C, Degos L: All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 38:13-25, 2001
3. Fenaux P, Le Deley MC, Castaigne S, et al: Effect of all trans retinoic acid in newly diagnosed promyelocytic leukemia: Results of a multicenter randomized trial European APL 91 Group. Blood 82:3241-3249, 1993
4. Fenaux P, Chevret S, Guerci A, et al: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL Group. Leukemia 14:1371-1377, 2000
5. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
6. Fenaux P, Chastang C, Chevret S, et al: A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94:1192-1200, 1999
7. Burnett AK, Grimwade D, Solomon E, et al: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC Trial. Blood 93:4131-4143, 1999
8. Estey E, Thall PF, Pierce S, et al: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483-490, 1997
9. Sanz MA, Lo Coco F, Martin G, et al: Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000
10. Lengfelder E, Reichert A, Schoch C, et al: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14:1362-1370, 2000
11. Diverio D, Rossi V, Avvisati G, et al: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92:784-789, 1998
12. Thomas X, Dombret H, Cordonnier C, et al: Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute Promyelocytic Leukemia. Leukemia 14:1006-1013, 2000
13. Ikezoe T, Daar ES, Hisatake JI, et al: HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96:3553-3559, 2000
14. Sun HD, Ma L, Hu XC: Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integral Chin West Med 1:170-171, 1992
15. Zhu J, Chen Z, Lallemand-Breitenbach V, et al: How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2:705-713, 2002
16. Zhang P, Wang SY, Hu LH: Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 2:58-62, 1996
17. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360, 1997
18. Soignet SL, Maslak P, Wang Z-G, et al: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348, 1998
19. Hu J, Shen ZX, Sun GL, et al: Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: An experience of 120 patients at a single institution. Int J Hematol 70:248-260, 1999
20. Niu C, Yan H, Yu T, et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324, 1999
21. Soignet SL, Frankel SR, Douer D, et al: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860, 2001
22. Kwong YL, Au WY, Chim CS, et al: Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study. Am J Hematol 66:274-279, 2001
23. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353, 1997
24. Dai J, Weinberg RS, Waxman S, et al: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93:268-277, 1999
25. Jing Y, Dai J, Chalmers-Redman RME, et al: Arsenic trioxide induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102-2111, 1999
26. Huang C, Ma WY, Li J, et al: Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59:3053-3058, 1999
27. Roboz GJ, Dias S, Lam G, et al: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525-1530, 2000
28. Chen Z, Chen GQ, Shen ZX, et al: Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies. Semin Hematol 38:26-36, 2001
29. Zhu J, Koken MH, Quignon F, et al: Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:3978-3983, 1997
30. Lallemand-Breitenbach V, Zhu J, Puvion F, et al: Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, US proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193:1361-1371, 2001
31. Altucci L, Rossin A, Raffelsberger W, et al: Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Med 7:680-686, 2001
32. Gianni M, Koken MH, Chelbi-Alix MK, et al: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91:4300-4310, 1998
33. Huang X: Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells. Chin Med J 113:498-501, 2000
34. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al: Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043-1052, 1999
35. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 97:10173-10178, 2000
36. Jing Y, Wang L, Xia L, et al: Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97:264-269, 2001
37. Au WY, Chim CS, Lie AK, et al: Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 117:130-132, 2002
38. Frankel SR, Eardley A, Lauwers G, et al: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296, 1992
39. De Botton S, Dombret H, Sanz M, et al: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92:2712-2718, 1998
40. Camacho LH, Soignet SL, Chanel S, et al: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18:2620-2625, 2000
41. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
42. Eclache V, Benzacken B, Le Roux G, et al: PML/RAR alpha rearrangement in acute promyelocytic leukaemia with t(1;17) elucidated using fluorescence in situ hybridization. Br J Haematol 98:440-443, 1997
43. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
44. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc 135:185-206, 1972
45. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
46. Castaigne S, Chomienne C, Daniel MT, et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 76:1704-1709, 1990
47. Meloni G, Diverio D, Vignetti M, et al: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90:1321-1325, 1997
48. Quignon F, De Bels F, Koken M, et al: PML induces a novel caspase-independent death process. Nat Genet 20:259-265, 1998
49. Guillemin MC, Raffoux E, Vitoux D, et al: Activation of cAMP signaling induces growth arrest and enhances differentiation in acute promyelocytic leukemia. J Exp Med 196:1373-1380, 2002